First-in-human single-dose KLA478 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center Phase 1 trial enrolls healthy volunteers in two parts: an open-label single-dose active-comparator arm to characterize the comparator's pharmacokinetics, followed by a randomized, double-blind, placebo-controlled single ascending dose (SAD) arm of KLA478. Participants are healthy adults aged 18–45 who meet weight and BMI criteria and undergo screening labs and clinical exams. Doses of KLA478 will be escalated across cohorts with close safety monitoring and serial blood sampling for pharmacokinetic analysis. The study collects safety, tolerability, and PK data to inform dosing for later-phase studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Sign the informed consent form
2. Health participants (Age: 18\~45 years);
3. Body Weight: Male≥50.0kg, Female≥45.0kg; 19 ≤BMI≤ 28.0kg/m2;
4. Clinical examination normal, or abnormal with no clinical significance；
5. Agreed to use contraception for 3-6 months.

Exclusion Criteria:

1. Allergy or Drug hypersensitivity;
2. Clinically significant Medical History；
3. Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia；
4. Assess injection site abnormalities；
5. History of drugs that may interact with pramipexole within 1 month；
6. History of any Medication within 2 weeks；
7. Massive blood loss (\> 200 mL) in the past 3 months；
8. History of any surgery within 3 months, or plan to undergo surgery during the trial；
9. History of any clinical study within 90 days；
10. History of any vaccine within 1 month，or Plan to get vaccinated during the trial period；
11. systolic blood pressure decreased ≥20 mmHg or diastolic blood pressure decreased ≥10 mmHg within 3 minutes from supine to upright position；
12. QTcF\>450 ms；
13. Abnormal vital signs with clinical significance ；
14. Serum potassium level exceeds the reference range.；
15. Pre-transfusion test abnormal；
16. Lactation or pregnancy test positive ；
17. History of any drug abuse or positive drugs of abuse test result；
18. Previous alcohol abuse or unwillingness to stop drinking or alcohol breath test positive；
19. more than 3 cigarettes per day in 3 months, or unwilling to stop during the trial；
20. Intake of special diets that affect drug absorption, distribution, metabolism and excretion within 48 hours；
21. Have special requirements for diet；
22. Unprotected sexual behavior within 2 weeks;
23. engaged in driving vehicles, operating machinery, high-altitude work or other potentially dangerous behavior;
24. Inappropriate for participation in this trial as judged by the investigator.

Where it's running

• Huashan Hospital Affiliated to Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Wei Qi
• Email: qiw@kelun.com
• Phone: 028-82339360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KL0011034 injection safety in healthy adults

  This study tests whether a single IV dose of KL0011034 is safe and tolerable in healthy volunteers aged 18–45.

  Recruiting Phase 1 Hunan Kelun Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07474545

• Single-dose KLA318-2 nanocrystal injection safety and PK test

  This trial will try one intravenous dose of KLA318-2 in healthy adults to see if it is safe, tolerable, and how the body processes it.

  Recruiting Phase 1 Hunan Kelun Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07171034

• First human single and multiple dose KLA578-1 injections

  This test will try single and multiple doses of KLA578-1 injections in healthy adults to see if the drug is safe and to measure how the body processes it.

  Recruiting Phase 1 Hunan Kelun Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07143318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.